Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00685945 · ClinicalTrials.gov registry record · NA
Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3
A NA study, sponsored by Vanderbilt University.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT00685945 is a NA study that has completed, run by Vanderbilt University. The registered enrollment target is 24 participants.
The verdict
NCT00685945, a NA study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if giving isosorbide,a drug that is used to treat chest pain, affects blood vessel release of an anti-clotting factor.
Interventions
- DRUG Control (bradykinin)
- DRUG L-NMMA + bradykinin
- DRUG Isosorbide + L-NMMA + bradykinin
- DRUG Sildenafil + L-NMMA + bradykinin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00685945
The ClinicalTrials.gov registry entry for NCT00685945 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Control (bradykinin) is the first listed.
NCT00685945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00685945 about?
NCT00685945 is a clinical study titled "Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3". The purpose of the study is to determine if giving isosorbide,a drug that is used to treat chest pain, affects blood vessel release of an anti-clotting factor.
What is the current status of trial NCT00685945?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2007-12. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00685945?
The interventions under investigation include: Control (bradykinin) (DRUG), L-NMMA + bradykinin (DRUG), Isosorbide + L-NMMA + bradykinin (DRUG), Sildenafil + L-NMMA + bradykinin (DRUG).
Who is sponsoring clinical trial NCT00685945?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.